Kornimate/medical-research-clean huggingface dataset:
feasibility study on the medical and economic consequences of outpatient management of tias and minor strokes

Conditions: Transient Ischemic Attack

Summary: the effectiveness of outpatient management of minor tias and strokes in the context of a dedicated outpatient pathway with specialized care has been demonstrated and has resulted in an 80% decrease in stroke in the year followed the ait (express and sos-tia studies) at the same time, few studies have been conducted on their economic interest and none in france. patient's typology (younger patient, no sequel, no disability) with transient ischemic attack (tia) and minor stroke (ms) makes them compatible with ambulatory management.

only two hospitals in france can take care patients with tia or ms in an outpatient setting :bichat hospital in paris and toulouse university hospital. the effectiveness of this management has been demonstrated since recurrence stroke risk is reduced by 80% at one year. an english study (express study) \[2\] showed a gain of 624 pounds with an ambulatory management compared to a conventional one. no studies are available in france on this subject. the aim of this study is to test the feasibility of a collection of medical and economic data on a prospective way. the investigators collect medical (cerebrovascular events, stroke) and economic (direct and indirect costs) data concerning patients who were managed in tia clinic in toulouse hospital. the medical data will be compiled with available french and international literature. the economic data will be compiled with available data in pmsi and health insurance database. this study aims to prepare a multicenter cohort to compare the cost effectiveness ratio between ambulatory and conventional management.

Eligibility criteria:
inclusion criteria: * hospitalization in the tia clinic in toulouse hospital (a day clinic) * having presented within the previous 7 days a transient ischemic attack or a minor stroke * affiliated to a social protection system * to have given no opposition to participation in the study exclusion criteria: * patients with a transient ischemic attack - mimic (such as migraine or seizure) * patients under protection of justice * pregnant and / or breastfeeding woman

Keywords: minor stroke cost-effectiveness feasibility day clinic
the feasibility of following the crohn's diet

Conditions: Crohn Disease; Inflammatory Bowel Diseases; Dietary Modification

Summary: a research team from king's college london are investigating how diet can be used as a treatment for crohn's disease. the investigators have designed a new diet and eventually wish to test whether the diet can be used to manage crohn's disease and reduce gut inflammation. before doing this, the investigators need to find out how practical it is for people to follow the diet for 14 days by conducting this 'feasibility' study. a feasibility study is a small study that aims to highlight any issues before informing the design of a larger research trial. the diet the investigators have designed is called the crohn's diet. the evidence for this diet is based on recent research which suggests that certain food ingredients may be involved in triggering gut inflammation. the study's primary aim is to assess the practicalities of following the crohn's diet. it will also assess compliance to the crohn's diet and if following it changes the nutritional balance from the normal diet.


Eligibility criteria:
inclusion criteria will include: 1. adults aged ≥18 years with a diagnosis of crohn's disease 2. stable crohn's disease (as defined as self-reported: no change in crohn's disease medication in the last 3 months; no crohn's disease surgery in the last 6 months; no hospital admissions related to crohn's disease in the last 6 months; no new perianal crohn's disease in the last 6 months). 3. individuals with a body mass index (bmi) of ≥ 18.5 kg/m2 4. individuals able to give informed consent 5. individuals able to understand and read english 6. individuals willing to provide consent in this study which involves a dietary change for 14 days exclusion criteria will include: 1. unexplained/unintentional weight loss in the past 6 months 2. major co-morbidities; for example, diabetes, coeliac disease, major active psychiatric conditions or current eating disorders. 3. current crohn's disease therapy with any of the following: corticosteroids, exclusive or partial enteral nutrition (liquid nutrition), and any participants prescribed oral nutrition supplements for nutrition support. 4. individuals who report to be pregnant or lactating 5. individuals with specific, complex dietary needs (based on the dietitian's judgment), such as multiple food allergies, in which the additional burden of the crohn's diet would pose a nutrition risk.
a study on the correlation between cotinine levels and aneurysm wall enhancement on hrmri.

Conditions: Cotinine Levels; Arterial Aneurysm Wall Enhancement on HRMRI

Summary: this study aims to collect clinical, laboratory, and imaging data from patients with unruptured intracranial aneurysms, and collect blood or urine samples for cotinine testing. the enrolled patients underwent high-resolution magnetic resonance angiography to detect whether the intracranial aneurysm wall was enhanced and classify the degree of enhancement. the purpose is to study the correlation between arterial aneurysm wall enhancement and cotinine levels

this study aims to explore the relationship between cotinine levels and the risk of intracranial aneurysm rupture by collecting imaging features and patient cotinine levels of unruptured intracranial aneurysms on high-resolution magnetic resonance imaging, combined with the prognosis of patients with aneurysms. previous studies have shown that the risk of intracranial aneurysm rupture in patients is related to the enhancement of the aneurysm wall on high-resolution magnetic resonance imaging. therefore, this study included patients who met the inclusion criteria for high-resolution magnetic resonance imaging and cotinine testing, and followed up on the imaging characteristics, prognostic scores, and aneurysm occlusion rate of arterial aneurysms in patients.

Eligibility criteria:
inclusion criteria: * age 18-75 years old, male or infertile female; * diagnosed as ia (intracranial aneurysm) through cta, mra, or dsa; and it is suitable for endovascular intervention treatment * the patient and/or their legal representative or guardian fully understand the research purpose, voluntarily participate and sign informed consent books; * patients willing to cooperate with high-resolution magnetic resonance imaging. * patients willing to follow up and evaluate according to clinical research protocol requirements exclusion criteria: * avm (arteriovenous malformation), moyamoya disease, or davf (dural arteriovenous fistula) related aneurysms; * patients with contraindications for high-resolution magnetic resonance imaging; * participants in clinical trials of other drugs or medical devices; * patients with severe underlying diseases and extremely poor clinical conditions who cannot tolerate general anesthesia surgery; * patients with poor compliance and inability to cooperate with follow-up; * possible or clear history of severe allergy to contrast agents; * patients with a life expectancy of less than 2 years; * women who are breastfeeding and preparing for pregnancy during the study period
effect of use of ureteral access sheath on levels of netrin-1 in patients undergoing rirs

Conditions: Urolithiasis

Summary: in this study, it is aimed to evaluate whether use of a ureteral access sheath (uas) during retrograde intrarenal surgery (rirs) due to kidney stone has any effect on protecting the kidney functions by measuring blood and urine and netrin-1 levels.

this study will include patients aged between 18 and 65 who will undergo retrograde intrarenal surgery (rirs) due to renal stone(s). a total of 60 patients (male or female) will be recruited, and will be randomized into 2 groups consisting of 30 patients in each group. the first group of patients will undergo rirs with a ureteral access sheath (uas) positioned prior to surgery; and the second group will undergo rirs without uas. as use of uas decreases the pressure in the renal pelvis during rirs, it is aimed to evaluate whether using uas or not affects the kidney functions. besides the routine kidney function tests, namely urea and creatinine, and netrin-1 (more specific and early marker of kidney function) will be used to assess the differences in the kidney functions. preoperative blood urea, creatinine and netrin-1 levels and urine netrin-1 levels will be studied for all patients. after the surgery, blood urea and creatinine levels will be again studied as well as blood netrin-1 levels at postoperative 48th hour; and urine netrin-1 levels at postoperative 24th hour.

Eligibility criteria:
inclusion criteria: * being between 18-65 years old * having an indication of retrograde infrarenal surgery (rirs) due to kidney stone exclusion criteria: * patients with uncontrolled diabetes mellitus and diabetic nephropathy * patients with blood pressure \> 140/80 mmhg despite regular use of antihypertensive agent(s) * patients with chronic kidney failure who need dialysis * patients who have had prerenal, renal or postrenal acute kidney failure 3 months or much earlier * patients who have had pyelonephritis 3 months or much earlier * patients younger than 18 years or older than 65 years * patients who have undergone a kidney surgery within the last 3 months and have abnormal kidney function tests * patients with a concomitant ureter stone who will undergo an endoscopic ureter stone treatment at the same session

Keywords: kidney stone retrograde intrarenal surgery ureteral access sheath kidney function
comparative study between fat injection and platelet rich plasma in post burn facial scar

Conditions: Burn Scar

Summary: best method in management of facial burn scar

the stages of wound healing:proceed in an organized way and follow four processes: hemostasis, inflammation, proliferation and maturation. although the stages of wound healing are linear, wounds can progress backward or forward depending on internal and external patient conditions. the four stages of wound healing are:hemostasis phase hemostasis is the process of the wound being closed by clotting. hemostasis starts when blood leaks out of the body. inflammatory phase inflammation is the second stage of wound healing and begins right after the injury when the injured blood vessels leak transudate (made of water, salt, and protein) causing localized swelling. proliferative phase the proliferative phase of wound healing is when the wound is rebuilt with new tissue made up of collagen and extracellular matrix. maturation phase also called the remodeling stage of wound healing, the maturation phase is when collagen is remodeled from type iii to type i and the wound fully closes. fat injection in facial burn scar:the effects of the lipofilling can be seen starting from 3 weeks after the procedure, in terms of better scar color, pliability, thickness, relief, itching, pain, scar vascularization and pigmentation. indeed, autologous fat grafting makes the skin softer, more flexible and extensible; besides, the color seems similar to the surrounding unharmed skin. platelet rich plasma in facial burn scar: impaired wound-healing and a long treatment course in severe burns as well as secondary complications originating from uncovered wounds motivate research to accelerate the wound-healing process and speed up re-epithelialization in burn patients.

Eligibility criteria:
inclusion criteria: 1. patients with post burn facial scar 2. age: 15 _60 yrs old 3. mature burn scar (after 3 months) exclusion criteria: 1. patients less than 15 yrs old 2. patients more than 60 yrs old 3. patients with comorbidies (hypertension-diabetes-thromboembolic diseases-immunocomprimized patients) 4. patients with burn scar in any site of body other than face
a pharmacokinetic study of subcutaneous and intravenous rituximab in participants with follicular lymphoma

Conditions: Lymphoma, Follicular

Summary: this 2 stage study will compare the pharmacokinetics and safety profile of subcutaneous and intravenous rituximab in participants with follicular lymphoma. in the first stage, participants who have achieved at least a partial response after induction treatment with intravenous rituximab will be randomized to one of 3 treatment cohorts, to receive rituximab 375 milligram per square meter (mg/m\^2) intravenously, 375 mg/m\^2 subcutaneously or 625 mg/m\^2 subcutaneously, and pharmacokinetics evaluated on an ongoing basis. upon selection of the subcutaneous dose (800 mg/m\^2) which results in rituximab trough plasma concentration (c trough) values comparable to those achieved with the intravenous formulation, participants in the second stage of the study will be randomized to receive either the subcutaneous or intravenous formulation to demonstrate comparability of the c trough levels with both routes of administration. maintenance therapy will continue every 2 or 3 months with the subcutaneous formulation.


Eligibility criteria:
inclusion criteria: * cd20-positive follicular non-hodgkin's lymphoma (nhl) * documented partial or complete response a the end of induction treatment with rituximab * must have completed induction treatment, and received at least 1 dose of intravenous rituximab maintenance treatment * eastern cooperative oncology group (ecog) performance status of less than and equal to (\<=) 2 * life expectancy of greater than and equal to (\>=) 6 months exclusion criteria: * histological evidence of transformation of nhl, or types of nhl other than follicular lymphoma * presence or history of central nervous system disease * history of malignancy other than follicular nhl * recent major surgery (within 4 weeks prior to screening), excluding lymph node biopsy
pharmacogenetics of response to sitagliptin (prs)

Conditions: Diabetes

Summary: this is a research study to find out how different people respond to a medication called sitagliptin. sitagliptin is an fda approved medication that is used to treat diabetes. we are asking for healthy, non-diabetic volunteers to participate in this 7-week study. if you agree to participate, you will take part in 2 clinic visits that are 4-6 weeks apart. at the clinic visits you will have an oral glucose tolerance test (ogtt) and other blood tests to see how your body processes glucose (sugar). an ogtt is a test in which your drink glucose and then blood samples are taken afterward at specific time points to measure glucose and insulin in your blood. each clinic visit will last about 5 hours.


Eligibility criteria:
inclusion criteria: * • age: \&gt;18 years old * members of old order amish community in lancaster, pa exclusion criteria: * • pregnancy (reproductive age women will undergo pregnancy tests immediately before receiving the drug) * diabetes: hba1c \&gt; 6.5% or fasting plasma glucose \&gt;126 mg/dl * estimated glomerular filtration rates (egfr) \&lt;60 ml/min/1.73 m2 * anemia: hematocrit \&lt; 35% * thyroid status: tsh\&lt;0.4 or tsh\&gt;5.5 * alt or ast in excess of 2x upper limit of normal * drugs that in the physician's judgment would alter response to sitagliptin * significant health issues that in the physician's judgment could increase the risk for participants.
at247, novorapid® and fiasp® in glucose clamp study

Conditions: Diabetes Mellitus, Type 1

Summary: a phase i, randomised, single-centre, double-blind, single-dose, three period, balanced cross over study in a glucose clamp setting. the study compares the pharmacodynamic, pharmacokinetic and safety characteristics of at247, novorapid® and fiasp® in male participants with type i diabetes mellitus.


Eligibility criteria:
inclusion criteria include: 1. diagnosis type i diabetes mellitus for at least 12 months 2. receiving treatment with multiple daily insulin injections or insulin pump therapy for at least 12 months 3. fasting c-peptide concentration ≤8.5% (≤69 mmol/mol) at screening 4. bmi 18.5-35.0 kg/m2 exclusion criteria include: 1. known or suspected hypersensitivity to investigational medicinal products 2. clinically significant concomitant disease or abnormal lab values 3. supine systolic bp outside range 95-140 mmhg and/or diastolic bp greater than 90 mmhg
a clinical trial to evaluate the safety, tolerability, and efficacy of subjects with plaque psoriasis

Conditions: Plaque Psoriasis

Summary: a multi-center, open-label, phase 2 clinical trial to evaluate the safety, tolerability, and efficacy of adx-629 administered orally to subjects with plaque psoriasis


Eligibility criteria:
inclusion criteria: * subject is a male or non-pregnant female 18 years of age or older. * subject has provided written informed consent. * females must be post-menopausal, surgically sterile, or use a highly effective method of birth control during the trial and for 30 days after the last administration of test article. women of childbearing potential (wocbp) must have a negative urine pregnancy test (upt) at visit 1/screening and visit 2/baseline. * male subjects who are not surgically sterile (e.g., vasectomy performed at least 6 months prior to trial entry) and are sexually active with a female partner who is of childbearing potential must agree to use an effective form of birth control for the duration of the trial and for 90 days after completion of treatment. * subject, in the investigator's opinion, is in good general health and free of any disease state or physical condition that might impair evaluation of plaque psoriasis or exposes the subject to an unacceptable risk by trial participation. exclusion criteria: * subject is pregnant, lactating, or is planning to become pregnant during the trial. * subject has a physical condition which, in the investigator's opinion, might impair evaluation of plaque psoriasis or which exposes the subject to an unacceptable risk by trial participation. * subject is currently enrolled in an investigational drug, biologic, or device trial. * subject has used an investigational drug, investigational biologic, or investigational device treatment within 30 days prior to visit 2/baseline.
validity of perfusion index to evaluate the level of general anaesthesia in children.

Conditions: Awareness, Anesthesia

Summary: the aim of this study is to evaluate the validity of perfusion index to determine the level of anesthesia in comparison with auditory evoked potential in children undergoing tonsillectomy.

the use of the perfusion index as an added monitoring tool during anesthesia provides the anesthetist with a number of benefits. it is a useful tool to forewarn the clinician of possible light planes of anesthesia, allowing for agent dose adjustment. it is a preexisting technology that is already widely available and used in most urban, regional,and rural centers, in both developed and developing countries, is noninvasive, continuous, and inexpensive. the aep monitor/2 (danmeter a/s, odense, denmark), a commercialized system for depth of anesthesia monitoring, extracts the middle latency auditory evoked potentials (mlaep) from the eeg-signal by using an autoregressive model with an exogenous input adaptive method

Eligibility criteria:
inclusion criteria: * patients aged 3-12 years * elective tonsillectomy due to recurrent or chronic tonsillitis exclusion criteria: * cerebral disease * cardiac disease, * renal disease, * pulmonary disease * hepatic disease.
a study evaluating efruxifermin in subjects with compensated cirrhosis due to nash/mash

Conditions: NASH - Nonalcoholic Steatohepatitis; MASH - Metabolic Dysfunction-Associated Steatohepatitis

Summary: this is a multi-center evaluation of efruxifermin (efx) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to nash/mash.


Eligibility criteria:
inclusion criteria: * cohort 1: biopsy proven compensated cirrhosis (fibrosis stage 4) due to nash/mash * cohort 2: biopsy proven or non-invasively diagnosed compensated cirrhosis (fibrosis stage 4) due to nash/mash exclusion criteria: * other causes of liver disease based on medical history and/or liver histology and/or central laboratory results * type 1 diabetes or unstable type 2 diabetes * any current or prior history of decompensated liver disease other inclusion and exclusion criteria may apply
better diabetes control, quality - educate to achieve compliance.

Conditions: Diabetes Type 2

Summary: prospective study to evaluate the impact of an educational programme about diabetes, comparing to normal clinical practice, on treatment compliance and disease control of people with type 2 diabetes followed in the primary care units in portugal

prospective study to evaluate the impact of an educational programme about diabetes focusing on treatment compliance, exercise and nutrition, comparing to normal clinical practice, on treatment compliance and disease control of people with type 2 diabetes followed in the primary care units in portugal.

Eligibility criteria:
inclusion criteria: * individuals with type 2 diabetes * hba1c \<= 8,5% * treated with oral antidiabetics for at least 6 months exclusion criteria: - treatment with insulin

Keywords: diabetes; compliance
pathophysiology and clinical relevance of endotoxin tolerance in humans

Conditions: Endotoxemia

Summary: a number of diseases lead to a so called systemic inflammatory response syndrome (sirs). this excessive response is self-destructive and leads to major complications of the initial disease: dysfunction of the microcirculation, systemic vasodilation, and increased capillary leakage and oedema. animal studies have shown that pre-treatment with endotoxin (lipopolysaccharide or lps) suppress the excessive immune response and when rechallenged, the animal survive a normally lethal dose of endotoxin. besides a diminished cytokine response, an increased production of leucocytes in the bone marrow and an increased phagocytosis after pre-treatment with endotoxin is seen. the combination of these factors: diminished systemic inflammatory response and increased cellular immunity makes that endotoxin tolerance is a useful tool for preventing the complications after an excessive inflammatory response. further, the presence of cross-tolerance has also been shown: endotoxin tolerant mice survive more after induction of a normally lethal fungal infection. endotoxin tolerance is also protective for ischemia/reperfusion injury in kidneys, heart and liver. little data is known about endotoxin tolerance in human. the purpose of this study is to induce a state of tolerance through 2 different administration schedules and monitor the effect of tolerance on pro- and anti-inflammatory cytokines, other inflammatory parameters and different proteins involved in the signalling pathway. the effects of tolerance on vascular reactivity will be determined. finally, the effect of tolerance on ischemia-reperfusion injury will be investigated.

see protocol

Eligibility criteria:
inclusion criteria: * healthy male volunteers exclusion criteria: * drug-, nicotine-, alcohol abuses * tendency towards fainting * bmi \< 18 kg/m2

Keywords: endotoxin tolerance humans cross-tolerance pro and anti-inflammatory cytokines